Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage...
-
NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
-
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12...
-
New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV,...
-
BRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2...
-
Asgard Therapeutics to present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy, at ASGCT 2026
-
Tevogen.AI nears PredicTcell completion, expands features to 290+, improves precision ~10%, and begins exploring co-development partnerships.
-
The Center for Cancer &Blood Disorders receives authorization to administer FDA-approved CAR T-cell therapy; begins treating 1st community oncology patient
-
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+...
-
Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Kawasaki Disease Market - A Global and Regional Analysis: Focus on Treatment Type and Region, 2025-2035" report has been added to ...